A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors.
Principal Investigator
Dr. M. van Dongen
Drugs
GSK5733584, an ADC (anti-B7-H4 IgG1 monoclonal antibody with topoisomerase I inhibitor (HS-9265)).
The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.
Read more on clinicaltrials.gov.